

China approves Ascendas microfluidics technology

15 October 2022 | News

Ascendas Genomics receives NMPA approval for use of standard biotools microfluidics technology to advance the development of molecular diagnostics in China



Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company's Biomark family of systems and its Juno system in NMPA molecular diagnostics services, enabling an important advance for microfluidics technology in the country.

Ascendas Genomics is an innovative molecular diagnostics company with experience in developing high-performing assays for disease risk screening. Recent NMPA approval obtained by Ascendas Genomics enables further development of molecular diagnostics into the clinical market in China, expanding the application of microfluidics products and services.

This announcement builds upon a longstanding strategic partnership between Standard BioTools and Ascendas Genomics, by which Ascendas Genomics has developed and commercialized molecular diagnostic systems and assays in China using microfluidics technologies included in the Standard BioTools Biomark real-time PCR and Juno systems.

Used by researchers around the world to detect somatic and genomic variations from patient samples, microfluidics technology offers highly scalable and automated workflows for quantitative PCR and enables the cost efficiencies, flexibility and proven analytical performance that laboratories need to meet the increasing demands of molecular testing.